Jazz Pharmaceuticals plc - SHS USD (JAZZ)

Historical Holders from Q1 2014 to Q3 2025

Symbol
JAZZ on Nasdaq
Type / Class
Equity / SHS USD
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
60,549,112
Holdings value
$7,977,831,227
% of all portfolios
0.013%
Number of holders
494
Number of buys
214
Number of sells
-254
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of Jazz Pharmaceuticals plc - SHS USD (JAZZ)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 60,549,112 $7,977,831,227 -$136,654,361 $131.8 494
2025 Q2 61,824,515 $6,561,677,298 +$172,218,482 $106.12 497
2025 Q1 59,973,813 $7,442,798,617 +$115,230,167 $124.15 545
2024 Q4 59,002,163 $7,265,494,814 +$147,830,867 $123.15 502
2024 Q3 57,597,455 $6,415,433,594 +$58,344,093 $111.41 469
2024 Q2 57,463,700 $6,133,341,626 -$38,433,148 $106.73 451
2024 Q1 57,711,183 $6,947,614,300 +$89,820,559 $120.42 475
2023 Q4 57,060,984 $7,017,863,210 -$56,981,989 $123 491
2023 Q3 56,530,271 $7,318,098,320 -$17,277,114 $129.44 482
2023 Q2 56,728,151 $7,039,068,770 -$22,114,573 $123.97 465
2023 Q1 56,681,319 $8,292,329,555 +$108,158,178 $146.33 462
2022 Q4 56,178,304 $8,948,272,058 -$100,056,709 $159.31 475
2022 Q3 56,928,016 $7,590,657,250 -$96,379,512 $133.29 443
2022 Q2 57,260,089 $8,932,716,610 +$138,065,500 $156.01 448
2022 Q1 56,748,008 $8,837,789,303 -$111,358,494 $155.67 437
2021 Q4 57,664,502 $7,350,056,970 +$21,422,030 $127.4 422
2021 Q3 56,879,540 $7,407,482,783 -$119,725,201 $130.21 422
2021 Q2 57,178,368 $10,156,395,395 +$780,868,772 $177.64 481
2021 Q1 53,127,709 $8,729,942,643 +$29,540,811 $164.37 435
2020 Q4 52,654,654 $8,685,222,791 -$294,935,573 $165.05 428
2020 Q3 54,543,371 $7,767,396,418 +$369,110,226 $142.59 382
2020 Q2 52,094,206 $5,741,576,836 +$270,141,092 $110.34 376
2020 Q1 49,800,360 $4,968,187,513 -$262,951,825 $99.74 397
2019 Q4 51,855,668 $7,738,313,733 +$162,667,912 $149.28 436
2019 Q3 50,956,459 $6,527,263,115 +$97,208,216 $128.14 397
2019 Q2 50,088,303 $7,125,707,525 +$206,804,403 $142.56 407
2019 Q1 51,378,205 $7,336,806,884 -$212,277,925 $142.95 415
2018 Q4 52,922,692 $6,549,889,371 -$427,140,677 $123.96 409
2018 Q3 55,400,378 $9,303,697,145 -$146,566,478 $168.13 397
2018 Q2 56,183,461 $9,670,926,964 +$435,954,554 $172.3 373
2018 Q1 53,679,721 $8,093,065,376 -$76,065,361 $150.99 320
2017 Q4 54,247,348 $7,295,659,971 -$66,672,908 $134.65 319
2017 Q3 54,642,574 $7,995,262,702 +$210,111,108 $146.25 299
2017 Q2 53,141,372 $8,263,546,157 +$374,758,650 $155.5 314
2017 Q1 52,283,523 $7,587,950,162 +$512,523,733 $145.13 302
2016 Q4 52,085,929 $5,676,848,580 -$158,899,374 $109.03 287
2016 Q3 53,391,287 $6,483,323,799 -$52,478,840 $121.48 317
2016 Q2 53,886,553 $7,614,644,976 -$43,527,577 $141.31 354
2016 Q1 54,554,481 $7,120,724,289 -$230,482,851 $130.55 330
2015 Q4 56,253,036 $7,906,867,974 -$16,787,687 $140.56 338
2015 Q3 56,363,725 $7,485,153,388 +$25,070,936 $132.81 350
2015 Q2 55,981,344 $9,856,454,549 +$619,952,018 $176.07 367
2015 Q1 52,457,739 $9,064,673,642 -$333,658,314 $172.79 352
2014 Q4 54,301,590 $8,892,764,640 +$176,201,808 $163.73 351
2014 Q3 53,225,671 $8,544,993,638 +$384,771,818 $160.56 320
2014 Q2 50,728,244 $7,457,848,518 +$45,563,248 $147.01 299
2014 Q1 50,472,408 $6,997,331,929 +$318,974,123 $138.68 310